Evoke Pharma (NASDAQ:EVOK) Now Covered by Analysts at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a research note issued to investors on Wednesday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Price Performance

Shares of NASDAQ:EVOK opened at $4.70 on Wednesday. The company has a market capitalization of $7.00 million, a price-to-earnings ratio of -0.43 and a beta of 0.36. The business’s 50-day moving average is $5.12 and its 200-day moving average is $5.49. Evoke Pharma has a 1 year low of $3.54 and a 1 year high of $17.40.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Evoke Pharma stock. Corsair Capital Management L.P. acquired a new stake in Evoke Pharma, Inc. (NASDAQ:EVOK) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned 1.42% of Evoke Pharma at the end of the most recent reporting period.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.